MX366223B - Proteinas vinculantes que comprenden al menos dos dominios de repeticion contra her2. - Google Patents

Proteinas vinculantes que comprenden al menos dos dominios de repeticion contra her2.

Info

Publication number
MX366223B
MX366223B MX2015006548A MX2015006548A MX366223B MX 366223 B MX366223 B MX 366223B MX 2015006548 A MX2015006548 A MX 2015006548A MX 2015006548 A MX2015006548 A MX 2015006548A MX 366223 B MX366223 B MX 366223B
Authority
MX
Mexico
Prior art keywords
repeat domains
binding proteins
against her2
domains against
repeat
Prior art date
Application number
MX2015006548A
Other languages
English (en)
Other versions
MX2015006548A (es
Inventor
Fiedler Ulrike
Strobel Heike
Dolado Igancio
Original Assignee
Molecular Partners Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Partners Ag filed Critical Molecular Partners Ag
Publication of MX2015006548A publication Critical patent/MX2015006548A/es
Publication of MX366223B publication Critical patent/MX366223B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cell Biology (AREA)

Abstract

La presente invención se refiere a una proteína vinculante o de unión, recombinante, que comprende al menos un primer y un segundo dominio de repetición, en donde cada uno de dichos dos dominios de repetición se vincula o une a la región extracelular del HER2 y en donde dichos dominios de repetición se vinculan o unen covalentemente.
MX2015006548A 2012-11-30 2013-12-02 Proteinas vinculantes que comprenden al menos dos dominios de repeticion contra her2. MX366223B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12195156.0A EP2738180A1 (en) 2012-11-30 2012-11-30 Binding proteins comprising at least two binding domains against HER2.
PCT/EP2013/075290 WO2014083208A1 (en) 2012-11-30 2013-12-02 Binding proteins comprising at least two repeat domains against her2

Publications (2)

Publication Number Publication Date
MX2015006548A MX2015006548A (es) 2015-10-15
MX366223B true MX366223B (es) 2019-07-03

Family

ID=47257683

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015006548A MX366223B (es) 2012-11-30 2013-12-02 Proteinas vinculantes que comprenden al menos dos dominios de repeticion contra her2.

Country Status (11)

Country Link
US (1) US10370414B2 (es)
EP (2) EP2738180A1 (es)
JP (1) JP6410724B2 (es)
KR (1) KR102290592B1 (es)
CN (1) CN104918959A (es)
AU (2) AU2013351096C9 (es)
CA (1) CA2892747C (es)
HK (1) HK1211297A1 (es)
MX (1) MX366223B (es)
RU (1) RU2664464C9 (es)
WO (1) WO2014083208A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR081361A1 (es) 2010-04-30 2012-08-29 Molecular Partners Ag Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
DK2643349T3 (da) * 2010-11-26 2019-11-25 Molecular Partners Ag Designede repeat-proteiner, der binder til serumalbumin
WO2014060365A1 (en) * 2012-10-15 2014-04-24 Universität Zürich Prorektorat Mnw Bispecific her2 ligands for cancer therapy
CN105209483B (zh) 2013-05-31 2021-07-27 分子组合公司 与肝细胞生长因子结合的设计锚蛋白重复蛋白
CA2931356A1 (en) 2013-11-27 2015-06-04 Zymeworks Inc. Bispecific antigen-binding constructs targeting her2
US10858405B2 (en) 2015-02-06 2020-12-08 Navigo Proteins Gmbh EGFR binding proteins
ES2953482T3 (es) 2015-04-02 2023-11-13 Molecular Partners Ag Dominios de repetición de anquirina diseñados con especificidad de unión para la albúmina sérica
CN107922483B (zh) 2015-07-16 2021-07-30 纳维格蛋白质有限公司 新型免疫球蛋白结合蛋白及其在亲和纯化中的用途
US10584152B2 (en) 2015-07-20 2020-03-10 Navigo Proteins Gmbh Binding proteins based on di-ubiquitin muteins and methods for generation
DK3325514T3 (da) * 2015-07-20 2019-12-16 Navigo Proteins Gmbh Her2-bindende proteiner baseret på di-ubiquitin-muteiner
US11813336B2 (en) 2016-05-04 2023-11-14 Navigo Proteins Gmbh Targeted compounds for the site-specific coupling of chemical moieties comprising a peptide linker
RU2627215C1 (ru) * 2016-05-24 2017-08-03 Федеральное государственное автономное образовательное учреждение высшего образования "Национальный исследовательский Нижегородский государственный университет им. Н.И. Лобачевского" Рекомбинантный таргетный токсин, специфичный к клеткам, экспрессирующим рецептор her2
WO2018029157A1 (en) 2016-08-11 2018-02-15 Navigo Proteins Gmbh Novel alkaline stable immunoglobulin-binding proteins
WO2018054971A1 (en) 2016-09-22 2018-03-29 Molecular Partners Ag Recombinant binding proteins and their use
EP3706804B1 (en) 2017-11-07 2022-02-23 Navigo Proteins GmbH Fusion proteins with specificity for ed-b and long serum half-life for diagnosis or treatment of cancer
EP3980444A1 (en) * 2019-06-04 2022-04-13 Molecular Partners AG Designed ankyrin repeat domain with improved stability
JP2022535107A (ja) * 2019-06-04 2022-08-04 モレキュラー パートナーズ アクチェンゲゼルシャフト 組換え４－１ｂｂ結合タンパク質及びそれらの使用
CN114206943A (zh) 2019-06-04 2022-03-18 分子伴侣公司 多特异性蛋白质
JP2022535415A (ja) * 2019-06-04 2022-08-08 モレキュラー パートナーズ アクチェンゲゼルシャフト 組換えｆａｐ結合タンパク質及びそれらの使用
MX2022007120A (es) 2019-12-11 2022-09-09 Molecular Partners Ag Proteínas de unión al complejo péptido-mhc recombinantes y su generación y uso.
PE20231074A1 (es) 2020-05-06 2023-07-17 Molecular Partners Ag Nuevas proteinas de union a repeticiones de anquirina y sus usos
IL298168A (en) 2020-05-14 2023-01-01 Molecular Partners Ag Multispecific proteins
EP4263607A1 (en) 2020-12-16 2023-10-25 Molecular Partners AG Novel slow-release prodrugs
WO2022190008A1 (en) 2021-03-09 2022-09-15 Molecular Partners Ag Protease cleavable prodrugs
EP4304729A1 (en) 2021-03-09 2024-01-17 Molecular Partners AG Novel darpin based cd123 engagers
BR112023018293A2 (pt) 2021-03-09 2023-10-31 Molecular Partners Ag Acopladores de célula t multiespecíficos à base de darpin
CA3211248A1 (en) 2021-03-09 2022-09-15 Nina RESCHKE Novel darpin based cd33 engagers
CA3239407A1 (en) 2021-12-14 2023-06-22 Simon FONTAINE Designed repeat domains with dual binding specificity and their use
WO2024028278A1 (en) 2022-08-01 2024-02-08 Molecular Partners Ag Charge modified designed repeat domains and their use
WO2024038307A1 (en) 2022-08-19 2024-02-22 Novartis Ag Dosing regimens for sars-cov-2 binding molecules

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5348867A (en) 1991-11-15 1994-09-20 George Georgiou Expression of proteins on bacterial surface
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
CA2196496A1 (en) 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
EP0975748B1 (en) 1997-04-23 2006-03-29 Universität Zürich Methods for identifying nucleic acid molecules encoding (poly)peptides that interact with target molecules
ES2280131T3 (es) 1998-12-02 2007-09-01 Adnexus Therapeutics, Inc. Fusiones de adn-proteina y utilizaciones de las mismas.
US7417130B2 (en) 2000-09-08 2008-08-26 University Of Zurich Collection of repeat proteins comprising repeat modules
CA2565827A1 (en) * 2004-05-05 2005-12-15 Merrimack Pharmaceuticals, Inc. Bispecific binding agents for modulating biological activity
KR20190035967A (ko) * 2004-07-22 2019-04-03 제넨테크, 인크. Ｈｅｒ２ 항체 조성물
MX2008000345A (es) 2005-07-08 2008-04-02 Univ Zuerich Visualizacion en fagos usando transcolocacion contraduccional de polipeptidos de fusion.
WO2007103515A2 (en) 2006-03-06 2007-09-13 Amunix, Inc. Unstructured recombinant polymers and uses thereof
CA2691386C (en) 2007-06-21 2014-12-23 Technische Universitaet Muenchen Biological active proteins having increased in vivo and/or in vitro stability
CA2700391A1 (en) 2007-09-24 2009-04-02 University Of Zuerich Designed armadillo repeat proteins
AU2008328784B2 (en) 2007-11-27 2014-03-27 Ablynx N.V. Immunoglobulin constructs
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
CN102272148A (zh) 2008-11-03 2011-12-07 分子组合公司 抑制vegf-a受体相互作用的结合蛋白
TW201120210A (en) * 2009-11-05 2011-06-16 Hoffmann La Roche Glycosylated repeat-motif-molecule conjugates
AR081361A1 (es) 2010-04-30 2012-08-29 Molecular Partners Ag Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
DK2643349T3 (da) 2010-11-26 2019-11-25 Molecular Partners Ag Designede repeat-proteiner, der binder til serumalbumin
WO2012149439A2 (en) 2011-04-29 2012-11-01 Janssen Biotech, Inc. Il4/il13 binding repeat proteins and uses
WO2012162418A1 (en) * 2011-05-23 2012-11-29 The University Of North Carolina At Chapel Hill Methods and compositions for heterodimeric targeting ligands
RU2014150224A (ru) 2012-06-28 2016-08-20 Молекьюлар Партнерс Аг Сконструированный белок с анкириновым повтором, связывающийся с фактором роста тромбоцитов
WO2014060365A1 (en) 2012-10-15 2014-04-24 Universität Zürich Prorektorat Mnw Bispecific her2 ligands for cancer therapy
CN105209483B (zh) 2013-05-31 2021-07-27 分子组合公司 与肝细胞生长因子结合的设计锚蛋白重复蛋白

Also Published As

Publication number Publication date
US10370414B2 (en) 2019-08-06
JP2015537044A (ja) 2015-12-24
AU2013351096C1 (en) 2018-11-08
US20150299265A1 (en) 2015-10-22
KR102290592B1 (ko) 2021-08-19
AU2013351096C9 (en) 2019-01-31
RU2015120663A (ru) 2017-01-10
RU2664464C9 (ru) 2018-12-19
AU2013351096A1 (en) 2015-07-09
CA2892747A1 (en) 2014-06-05
JP6410724B2 (ja) 2018-10-24
WO2014083208A9 (en) 2014-12-24
AU2018256592A1 (en) 2018-11-22
KR20150091138A (ko) 2015-08-07
BR112015012436A2 (pt) 2017-09-12
WO2014083208A8 (en) 2014-10-30
CA2892747C (en) 2022-07-19
MX2015006548A (es) 2015-10-15
AU2013351096B2 (en) 2018-08-09
CN104918959A (zh) 2015-09-16
EP2925784A1 (en) 2015-10-07
WO2014083208A1 (en) 2014-06-05
EP2738180A1 (en) 2014-06-04
RU2664464C2 (ru) 2018-08-17
HK1211297A1 (en) 2016-05-20
EP2925784B1 (en) 2021-02-17

Similar Documents

Publication Publication Date Title
MX2015006548A (es) Proteinas vinculantes que comprenden al menos dos dominios de repeticion contra her2.
CY1119567T1 (el) Θεραπευτικα πεπτιδια
IN2012DN00640A (es)
MX347535B (es) Proteinas de union modificadas que inhiben la interaccion de receptor vegf-a.
MY164906A (en) Dual variable region antibody-like binding proteins having cross-over binding region orientation
BR112014019579A2 (pt) Anticorpo de cadeia única, polinucleotídeo, vetor, célula hospedeira, método de produção de um anticorpo de cadeia única, heteromultímero e método de produção do heteromultímero
NZ700891A (en) 4-1bb binding molecules
SG10201902924RA (en) Antibodies that bind ebola glycoprotein and uses thereof
IN2015MN00139A (es)
EA201291065A1 (ru) Антитела против vla-4
MX2019007921A (es) Nuevos agentes de union a ha.
MX2015011075A (es) Peptidos terapeuticos.
UA110049C2 (uk) ЛІКУВАННЯ ОСТЕОАРТРИТУ ІМУНОГЛОБУЛІНОВИМ ЗВ'ЯЗУВАЛЬНИМ БІЛКОМ З ПОДВІЙНИМ ВАРІАБЕЛЬНИМ ДОМЕНОМ, ЩО ЗВ'ЯЗУЄ IL-1α І IL-1β
CY1120824T1 (el) Μεθοδοι αυξησης περιεχομενου μαννοζης ανασυνδυασμενων πρωτεϊνων
MX2011008752A (es) Variantes de union a anti-albumina de suero mejoradas.
MX2012013406A (es) Variantes de union mejoradas anti-albumina serica.
TR201903403T4 (tr) İmmünoglobulin preparatı.
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
MX2011008749A (es) Variantes de union a anti-albumina de suero mejoradas.
PH12015500752A1 (en) Her3 antigen binding proteins binding to the beta-hairpin of her3
PH12014501818A1 (en) Pseudomonas aeruginosa pcrv binding single variable domain antibodies
PH12019500677A1 (en) Cmet monoclonal binding agents, drug conjugates thereof and uses thereof
MX2015013803A (es) Proteina de fusion de enlace al cartilago.
MX2016000344A (es) Un conjugado de fc de inmunoglobulina que mantiene la afinidad de union del fragmento fc de inmunoglobulina hacia fcrn.
EA201390955A1 (ru) Слитый белок robo1-fc для применения в лечении гепатокарциномы

Legal Events

Date Code Title Description
FG Grant or registration